Lopiten

Quick links to important sections

Lopiten

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lopiten

Quick Facts

Property Description
Active ingredient Amlodipine (typically as Amlodipine besilate)
Form Oral tablet (most common)
Pharmacological class Dihydropyridine Calcium Channel Blocker
General purpose Sustained management of high blood pressure
Origin Synthetic compound

What Type of Medicine is Lopiten (Amlodipine)?

Lopiten is the trade name for a prescription-only medication based on the active substance Amlodipine, a synthetic compound manufactured for pharmaceutical use. Amlodipine is formally classified as a Calcium Channel Blocker (CCB), belonging specifically to the Dihydropyridine pharmacological group, which indicates its selective action primarily on blood vessels. This chemical structure provides unique binding properties that support a distinguishing once-daily dosing regimen, clinically recognized for adherence. The drug is typically supplied for oral consumption, most commonly formulated as an oral tablet containing Amlodipine besilate, and it can be used either as a single product or as a component within a combination product.

What is the General Purpose of Taking Lopiten?

The general purpose of taking Lopiten is to support and maintain stable cardiovascular function by ensuring efficient blood flow. The drug’s main action is to cause vasodilation (widening of the arteries), which directly lowers the peripheral vascular resistance. Amlodipine is well-established as an effective agent in the management of elevated blood pressure, achieving its goal by relaxing the smooth muscles within the vessel walls. The overall benefit is thus the sustained reduction of high blood pressure and an improved supply of oxygen-rich blood to the heart muscle. This action provides consistent 24-hour support to the circulatory system.

What side effects are possible with Lopiten?

Possible side effects and safety information

Adverse reactions to Lopiten (Amlodipine) are formally classified by regulatory authorities based on their expected frequency and the affected body system. This profile strictly details the potential side effects and safety considerations documented in official government prescribing information.


Frequency-Classified Adverse Reactions

The most commonly reported adverse event is Oedema (swelling, typically of the ankles or feet), which is classified as Very Common. Other reactions reported as Common include Headache, Dizziness, Somnolence (drowsiness), Fatigue, Flushing, and gastrointestinal effects like Abdominal Pain and Nausea.

Effects classified as Uncommon or Rare involve a wide range of systems, including Musculoskeletal (muscle cramps), Skin (rash, pruritus), and Nervous System (tremor, hypoesthesia).


Serious Adverse Reactions and Safety Considerations

The official label documents rare but serious adverse reactions, which include cardiovascular events such as Myocardial Infarction and certain Arrhythmias. Severe skin reactions, including Angioedema and Stevens-Johnson Syndrome, are also officially listed as very rare but critical events.

Time- and Dose-Related Patterns: Regulatory documentation notes that certain effects, particularly peripheral Oedema and Headache, are sometimes more frequently observed at the start of treatment and that peripheral swelling is often dose-dependent.

Population-Specific Safety Notes: Caution is documented for use in individuals with Severe Hepatic Impairment, as the medicine is extensively metabolized by the liver, potentially leading to increased drug concentrations. Similarly, Older Adults may experience decreased clearance and a resulting increase in drug plasma levels, requiring careful consideration.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lopiten (Amlodipine) overdose is centered on the profound and sustained cardiovascular effects resulting from excessive drug exposure.

Feature Official Regulatory Statement
Documented Manifestations Marked and potentially prolonged systemic hypotension (severe drop in blood pressure); Excessive peripheral vasodilatation; Possible reflex tachycardia; Non-cardiogenic pulmonary edema (reported complication).
Severe Outcomes Overdosage has been associated with severe systemic hypotension that may progress to shock, which includes reported cases with a fatal outcome.
Mandatory Action Seek emergency medical attention immediately. Clinically significant hypotension requires immediate active cardiovascular support by medical professionals.
Antidote Status No specific antidote is known; treatment focuses exclusively on symptomatic and supportive measures.

The long elimination half-life of Amlodipine (30–50 hours) is a critical consideration in overdose management, necessitating an extended period of clinical monitoring and frequent monitoring of cardiac and respiratory function to manage persistent hemodynamic effects. For patients with impaired hepatic function, management requires particular caution due to a potentially prolonged half-life and corresponding higher drug exposure. Supportive procedures described in regulatory texts include the potential use of gastric lavage, activated charcoal, and the measured use of a vasoconstrictor to restore vascular tone if blood pressure remains low despite fluid support.

Therapeutic Uses of Lopiten

Lopiten is indicated for the supportive management of symptoms associated with specific conditions. It serves as a therapeutic option to help address general physical unease and temporary, functional somatic distress. The primary role of this medication is to assist in providing relief for symptoms that impact routine comfort and daily function. Commonly managed situations include periods of heightened bodily tension and difficulties achieving a state of routine calm.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lopiten (Amlodipine) — Official Regulatory Information

Official documents define eligibility based on specific physiological states, age, and existing health conditions, determining who may use the medicine and who is prohibited from use.


Eligibility Scope

Classification Population/Condition Regulatory Status
Contraindicated Hypersensitivity to Amlodipine or Dihydropyridines Absolute Exclusion
Severe Hypotension or Cardiogenic Shock Absolute Exclusion
Obstruction of the left ventricular outflow tract (e.g., severe Aortic Stenosis) Absolute Exclusion
Allowed Adult Patients (18 years and older) Established Use
Pediatric Patients (ages 6 to 17 years) for hypertension Established Use
Conditional/Caution Older Adults (Geriatric) Lower starting dose required
Hepatic Impairment (Liver Function) Lower starting dose required
Pregnant Individuals Use only if benefit justifies risk
Individuals who are Breastfeeding (Lactation) Not Recommended/Discontinue drug or nursing
Not Established Children under 6 years of age Safety and efficacy not known

Connection to the Overall Eligibility Profile

Regulatory agencies strictly define eligibility by listing absolute contraindications (such as shock or known drug sensitivity) which prohibit use. Use is officially established for adults and for pediatric patients aged 6 to 17 years. Patients with physiological limitations, including hepatic impairment and older adults, require special caution and a lower initial dose. The status of use during pregnancy and lactation is generally conditional or not recommended due to limited or insufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lopiten, which contains the active substance Amlodipine, engages in formally documented pharmacokinetic and pharmacodynamic interactions with certain substances and other medicinal products, as specified in regulatory labeling.

Documented Pharmacokinetic Interactions

Amlodipine's metabolism is primarily dependent on the CYP3A4 enzyme system. Co-administration with strong or moderate CYP3A4 Inhibitors (e.g., Diltiazem, Ketoconazole) is documented to increase the plasma concentration (exposure) of Amlodipine. Conversely, the co-administration of CYP3A4 Inducers (e.g., Rifampicin) may decrease Amlodipine concentration.

In addition, Amlodipine increases the exposure of Simvastatin. The official regulatory restriction requires that the dose of Simvastatin must not exceed 20 mg daily when co-administered with Amlodipine.

Contraindications and Other Interactions

Classification Official Regulatory Constraint
Formal Contraindication Contraindicated with Aliskiren (in combination products containing an ARB/ACEI) in patients with Diabetes
Pharmacodynamic Effect Co-administration with other anti-hypertensive agents results in an additive blood pressure-lowering effect
Food/Substance Interaction Consumption of large amounts of Grapefruit or Grapefruit Juice may lead to an increase in Amlodipine concentration

Population-Specific Notes

The clearance of Amlodipine is formally noted as being reduced in patients with hepatic impairment, resulting in prolonged exposure.

Mechanism of Action

How Lopiten Works: Mechanism of Action

Lopiten modulates the circulatory system by specifically interfering with the transport of calcium ions ( Ca^2+) within the blood vessel walls. This targeted interaction leads to predictable physiological adjustments that shape the resulting physiological effect.


Modulating Vascular Muscle Contraction

Lopiten acts as an antagonist by selectively blocking L-type voltage-dependent calcium channels located on vascular smooth muscle cells. This prevents the necessary influx of extracellular calcium ions, which are the main triggers for muscle contraction, thus initiating a cascade that leads directly to vascular muscle relaxation (vasodilation).


Reducing Peripheral Resistance

The resulting widespread relaxation of the arteries and arterioles lowers the peripheral vascular resistance throughout the body. This mechanistic influence contributes to the modulation of contractile signaling within the targeted pathways by lowering the total peripheral resistance (afterload) encountered by the heart during ejection.


Influencing Coronary Blood Supply

This mechanism causes the coronary arteries to widen, increasing the pathway for blood flow directly to the heart muscle. This modulation influences the regulation of processes driven by local signaling patterns, leading to an increased supply of oxygenated blood to the myocardium.

Dosage and Administration Information

How to Use Lopiten

This section outlines the general principles for administering Lopiten (Amlodipine), detailing the route, standard dosage ranges, and procedural schedules.


Administration Scope

Parameter Instruction
Route of administration The medication is for oral (by mouth) administration only.
Dosing schedule The standard initial dose for adults with hypertension or angina is 5 mg once daily. The usual maintenance dose ranges from 5 mg to 10 mg once daily, which is also the maximum recommended daily dose.
Timing in relation to meals Lopiten may be taken with or without food.
Age-group administration rules A starting dose of 2.5 mg once daily is designated for small/fragile adults, older adults, and those with hepatic insufficiency. The dose for pediatric patients (ages 6–17) is 2.5 mg to 5 mg once daily.
Missed-dose rule If a dose is missed, it should be taken as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Resulting Procedural Structure

The usage protocol establishes that Lopiten is intended for chronic, long-term administration. The medication is taken once daily, with the specific time of day being consistent. Dosage adjustments, or titration, should be performed gradually, with at least 7 to 14 days elapsing between changes to a higher dose to fully gauge therapeutic response. This structured, time-controlled approach dictates the entire continuous administration pattern of the drug.

Recent Clinical Evidence

Research Evidence for Lopiten (Amlodipine)

This overview summarizes the official research, primarily large randomized controlled trials (RCTs), that regulators use to evaluate Lopiten (Amlodipine). This focuses strictly on the structure of the evidence and what was measured.


Evidence for use in Essential Hypertension

The evidence foundation comes from numerous large-scale RCTs that compared amlodipine-based regimens against placebo. Research monitored changes in Systolic and Diastolic Blood Pressure (BP) over short periods and in longer-term observation settings. Long-term studies spanning several years explored the occurrence rates of major cardiovascular events in observed groups. Studies reported measurements of how blood pressure evolved and described the occurrence of major cardiovascular events. Long-term cardiovascular outcomes are not fully established when amlodipine is studied as a single agent.


Evidence for use in Chronic Stable Angina and Vasospastic Angina

Lopiten was evaluated in research cohorts experiencing chest pain symptoms. Trials examined outcomes related to physical discomfort, primarily measuring the frequency of self-reported angina episodes and the use of relief medications as a patient-reported outcome. Research highlights that studies monitored in the short term reported that some patients receiving amlodipine described fewer angina episodes compared to the placebo group. Evidence remains limited regarding the long-term durability of these measured changes.


Evidence for use in Coronary Artery Disease (CAD)

Research included long-term RCTs exploring outcomes in patients with documented artery disease (CAD). The outcomes examined included the rates of subsequent coronary revascularization procedures and major events like non-fatal myocardial infarction. Studies reported that groups receiving amlodipine exhibited different measured rates of hospitalization for unstable angina and revascularization procedures compared to the placebo group. However, some studies did not describe a measured difference regarding the progression of artery blockage.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Hypertension in adults: diagnosis and management (NG136)

Frequently Asked Questions (FAQ)

Common questions about Lopiten (FAQ)

Q: What is the expected timeframe for Lopiten to start having an effect?

A: According to official patient information, the medication generally begins to affect the body on the first day of treatment. However, the full therapeutic effect, which is necessary for sustained management of blood pressure, may take a couple of weeks to become apparent.

Q: How will a patient know if Lopiten is working as intended?

A: Because Lopiten is intended to lower blood pressure, which often has no noticeable symptoms, a patient may not be aware of any physical change when taking it. Therefore, official sources indicate that continued use is necessary for clinical effectiveness, which is monitored by a healthcare professional.

Q: Is there a generic version of Lopiten available, and is it considered equivalent?

A: Lopiten contains the active ingredient Amlodipine, which is widely available as a generic product. The generic version is subject to the same strict regulatory standards for quality and performance as the brand-name version.

Q: Is it safe to consume alcohol in moderation while taking Lopiten?

A: Alcohol (ethanol) and Lopiten may have an additive effect in lowering blood pressure. This effect may result in symptoms like dizziness or lightheadedness. Official guidance indicates caution may be warranted, especially when first starting the medication.

Q: Are there any specific dietary restrictions or foods to avoid with Lopiten?

A: Regulatory documents only explicitly advise that the consumption of large amounts of Grapefruit or Grapefruit Juice may lead to an increase in the medicine's concentration in the blood. No other specific food restrictions are typically noted in the official guidance.

Q: Can Lopiten be taken with herbal supplements or common vitamins?

A: Official documents advise caution regarding co-administration with other products, noting that multivitamins with minerals may potentially decrease the effects of Lopiten. Official documents emphasize the importance of communicating all supplements or herbs to the prescriber due to potential interactions.

Q: Is Lopiten use restricted for patients who have kidney problems?

A: Official documents state that the medicine's effects in the body are not significantly influenced by renal impairment (kidney disease). Because of this, patients with renal failure may typically receive the customary starting dose.

Q: Is it safe to cut or crush the Lopiten tablet or capsule?

A: The medication should typically be swallowed whole. Specific regulatory guidance often advises patients not to cut, crush, or chew the tablets, as this can affect how the medicine is absorbed in the body.

Q: Why do some patients report feeling worse when they first start taking Lopiten?

A: Certain common side effects, such as headache or peripheral swelling (oedema), are officially noted as sometimes being more frequently observed at the start of treatment. These effects are generally related to the body adjusting to the medication's action.

Q: What happens if a patient stops taking Lopiten suddenly?

A: Abruptly stopping antihypertensive medication can, in some cases, result in a rapid return or overshoot of blood pressure, which is sometimes associated with a withdrawal syndrome. For this reason, any change in medication is typically managed by a prescriber.

Q: What is the current status of research on Lopiten for conditions other than its main use?

A: Research studies have been conducted to explore the use of the active substance in the management of other conditions beyond its primary approved use. These may include conditions such as Raynaud’s Syndrome and for Migraine Prevention.

Q: Can caffeine affect how Lopiten works in the body?

A: Caffeine is an ingredient found in certain combination products that can increase blood pressure and heart rate. This action may potentially counteract the intended blood pressure-lowering effects of Lopiten, which typically requires clinical evaluation.

Q: Do the common side effects of Lopiten usually go away over time?

A: Documented effects like peripheral swelling (oedema) and headache are sometimes reported more frequently at the start of treatment; however, official documents do not promise that all common side effects will resolve completely.

Q: Does Lopiten cause drowsiness or sedation that affects driving?

A: Since common side effects include dizziness and somnolence (drowsiness), official caution is advised regarding activities that require alertness. This includes driving or operating hazardous machinery. Official guidance suggests deferring such activities until the individual's reaction to the medicine is understood.

Q: Does Lopiten interact with blood pressure medications or blood thinners?

A: Official documents note that co-administration with other anti-hypertensive agents results in an additive blood pressure-lowering effect. They also note interactions with other specific medications, but do not specifically name the class of blood thinners (anticoagulants).

Q: What kind of research has been conducted on the long-term safety of Lopiten?

A: The research foundation includes long-term randomized controlled trials (RCTs) exploring the occurrence rates of major cardiovascular events in observed patient groups over periods spanning several years.

Q: Are there different forms of Lopiten (e.g., liquid, extended-release)?

A: Lopiten is most commonly supplied as an oral tablet. Specific regulatory guidance for some related products advises patients to swallow tablets whole and not cut or crush them, which applies to forms that require controlled release.

Q: What is the reason Lopiten is contraindicated for certain groups of people?

A: Lopiten is contraindicated in conditions such as Severe Hypotension and Cardiogenic Shock because its mechanism of action (vasodilation) could potentially worsen the underlying severe cardiovascular instability in these patients.

Q: Is it true that Lopiten can cause changes to mood or sleep patterns?

A: Psychiatric adverse reactions officially listed as uncommon include insomnia (difficulty sleeping) and mood changes. These changes may encompass anxiety or depression.

Q: Is there a known risk of physical or psychological dependence with Lopiten?

A: Official regulatory safety warnings and adverse event lists do not describe a known risk of physical or psychological dependence associated with the use of Lopiten.

Q: Can Lopiten cause unintended changes in body weight or appetite?

A: Changes in appetite (increase or loss) and weight (gain or loss, sometimes due to swelling) have been listed among the officially documented side effects in regulatory documents.

Q: Can Lopiten affect the results of routine blood work or lab tests?

A: Research evidence suggests that the medicine may alter certain hemorheological parameters (properties of blood flow) that may be measured in some types of laboratory analysis.

Q: Does Lopiten interact with common over-the-counter cold and flu medicines?

A: Certain active ingredients commonly found in over-the-counter cold and flu medicines (known as sympathomimetic agents) may cause adverse cardiovascular effects. Official documents indicate that caution may be warranted in susceptible patients taking Lopiten.

How should Lopiten be stored and disposed of?

The official regulatory requirements for storing Lopiten (amlodipine besylate) tablets specify conditions necessary to maintain drug quality and stability.

Storage Requirements

  • Temperature and Environment: The tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, light, and excess moisture.
  • Container: The medicine must be kept in the container it came in, tightly closed, and preserved in light-resistant containers.
  • Child Safety: It is mandatory to keep this and all medicines out of the reach of children.

Disposal Instructions

  • General Rule: Unused or expired Lopiten must be disposed of according to federal, state, and local requirements.
  • Best Practice: The preferred method is through an official drug take-back program. Disposal in household trash requires mixing the product with an undesirable substance (like coffee grounds or kitty litter) in a sealed container; disposal down the sink or toilet is prohibited unless specifically directed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lopiten found in:

A-Z Index: